Lyell Immunopharma Inc. Common Stock (LYEL)
Stock · NASDAQ · Health Care
$8.12as of 10/16/2026
Price chart
Active signals
LYEL Signal Track Record
How signals performed across all stocks →What LYEL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | -4.9% | 35% | September 18, 2026 |
| Bollinger Band Breakout | 24 | -9.6% | 33% | August 7, 2026 |
| Bollinger Band Breakdown | 18 | -11.4% | 28% | September 9, 2026 |
| 200-Day Moving Average TouchActive now | 5 | -12.2% | 40% | April 30, 2026 |
| Any 20-session window (baseline) | -4.2% | 42% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About LYEL
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 161
- Website
- lyell.com/
Fundamentals
- 1-day range
- $7.76$8.44
- Market cap
- $348.21M
- P/E (trailing)
- —
- P/E (forward)
- -1.30
- EPS (trailing)
- $-12.01
- Dividend yield
- —
- Beta
- -0.04
- Avg. volume
- 149.3K
How Lyell Immunopharma Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 12, 2026 · via SEC EDGAR / Finnhub
Forecasts
8 analyst ratings
Lyell Immunopharma Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- LYELLyell Immunopharma Inc. Common Stock$8.12▼ 0.85%Market cap $348.21MP/E —$7.2$45
- ZNTLZentalis Pharmaceuticals Inc. Common Stock$2.13▼ 4.91%Market cap $355.93MP/E —$1.21$6.95
- NATRNature's Sunshine Products Inc. Common Stock$12.64▲ 0.00%Market cap $357.68MP/E 12.66$12.8$28.14
- CATXPerspective Therapeutics Inc. Common Stock$2.17▼ 7.26%Market cap $338.72MP/E —$1.96$6.16
- DMACDiaMedica Therapeutics Inc. Common Stock$7.57▼ 5.85%Market cap $364.79MP/E —$5.25$10.42
- FHTXFoghorn Therapeutics Inc. Common Stock$1.85▼ 2.12%Market cap $327.04MP/E —$1.79$7.61
- GALTGalectin Therapeutics Inc. Common Stock$3.62▼ 2.43%Market cap $324.74MP/E —$2.03$7.13
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| LYEL Lyell Immunopharma Inc. Common Stock | $348.21M | — | $8.12 | ▼ 0.85% | $7.2$45 |
| ZNTL Zentalis Pharmaceuticals Inc. Common Stock | $355.93M | — | $2.13 | ▼ 4.91% | $1.21$6.95 |
| NATR Nature's Sunshine Products Inc. Common Stock | $357.68M | 12.66 | $12.64 | ▲ 0.00% | $12.8$28.14 |
| CATX Perspective Therapeutics Inc. Common Stock | $338.72M | — | $2.17 | ▼ 7.26% | $1.96$6.16 |
| DMAC DiaMedica Therapeutics Inc. Common Stock | $364.79M | — | $7.57 | ▼ 5.85% | $5.25$10.42 |
| FHTX Foghorn Therapeutics Inc. Common Stock | $327.04M | — | $1.85 | ▼ 2.12% | $1.79$7.61 |
| GALT Galectin Therapeutics Inc. Common Stock | $324.74M | — | $3.62 | ▼ 2.43% | $2.03$7.13 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Lee Gary K. · August 21, 2026 · Sale1.5K @ $15.54
- Hill Stephen J. · August 21, 2026 · Sale989 @ $15.54
- Seely Lynn · August 21, 2026 · Sale9.6K @ $15.54
- Bulis Veronica Sanchez · August 10, 2026 · Sale621 @ $14.34
- Lee Gary K. · August 10, 2026 · Sale131 @ $14.34
- Hill Stephen J. · August 10, 2026 · Sale89 @ $14.34
- Seely Lynn · August 10, 2026 · Sale390 @ $14.34
- Innovative Cellular Therapeutics Holdings Ltd · July 27, 2026 · J44.0K
- Innovative Cellular Therapeutics Holdings Ltd · July 27, 2026 · J38.5K
- Innovative Cellular Therapeutics Holdings Ltd · July 17, 2026 · Sale10 @ $13.7
- Innovative Cellular Therapeutics Holdings Ltd · July 16, 2026 · Sale10 @ $13.73
- Innovative Cellular Therapeutics Holdings Ltd · June 29, 2026 · J76.0K
- David Shook · June 10, 2026 · Sale2.0K @ $12.64
- Bachleda Mark · June 10, 2026 · Grant9.3K
- Elizabeth G. Nabel · June 10, 2026 · Grant9.3K
Institutional Ownership
March 31, 2026
- Total shares held
- 11.87M
- Total value held
- $234.98M
- Institutional holders
- 71
- Unknown3.25M
- Unknown1.51M
- Unknown800.4K
- Unknown754.7K
- Unknown718.2K
- Unknown577.8K
- Unknown477.1K
- Unknown458.9K
- Unknown393.5K
- Unknown337.7K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Lyell Immunopharma shares fall 27% over four weeks
The stock has dropped about 27% in the past month, prompting a Yahoo article that discusses factors that could support a recovery. The piece notes the recent price weakness and points to potential catalysts that may improve sentiment. The decline leaves the share price near a key support level and the RSI is low, indicating oversold conditions.
Lyell Immunopharma shares fall 27% over four weeks. The stock has dropped about 27% in the past month, prompting a Yahoo article that discusses factors that could support a recovery. The piece notes the recent price weakness and points to potential catalysts that may improve sentiment. The decline leaves the share price near a key support level and the RSI is low, indicating oversold conditions.